

RECTAL
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE: SATURDAY, APRIL 29th, 2017

TIME: 09:00 – 10:00

CHAIRS: DR. HAGEN KENNECKE & DR. REBECCA AUER

- 09:00 WELCOME AND INTRODUCTION **DR. H. KENNECKE / DR. R. AUER**
- 09:00 ACTIVE/RECENTLY CLOSED TRIALS FOR UPDATE
CRC.7 (NCCTG N1048- PROSPECT): A PHASE II/III TRIAL OF NEOADJUVANT FOLFOX, WITH SELECTIVE USE OF COMBINED MODALITY CHEMORADIATION VERSUS PREOPERATIVE COMBINED MODALITY CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER PATIENTS UNDERGOING LOW ANTERIOR RESECTION WITH TOTAL MESORECTAL EXCISION **DR. H. KENNECKE**
- IND 228:** A PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED RARE TUMOURS (ANAL CANCER COHORT) **DR. R. AUER**
- 09:10 APPROVED TRIALS IN DEVELOPMENT
CO.28: NEOADJUVANT CHEMOTHERAPY, EXCISION AND OBSERVATION FOR EARLY RECTAL CANCER: THE NEO TRIAL **DR. C. BROWN / DR. H. KENNECKE**
- 09:25 NEW CONCEPTS IN DEVELOPMENT
SPAR STUDY (AGITG): A RANDOMISED, PLACEBO-CONTROLLED PHASE II TRIAL OF SIMVASTATIN IN ADDITION TO STANDARD CHEMOTHERAPY AND RADIATION IN PREOPERATIVE TREATMENT FOR RECTAL CANCER **DR. H. KENNECKE**
- 09:40 INTERGROUP TASK FORCE UPDATE
TNT (NRG GI-002): A PHASE II CLINICAL TRIAL PLATFORM OF SENSITIZATION UTILIZING TOTAL NEOADJUVANT THERAPY (TNT) IN RECTAL CANCER **DR. H. KENNECKE**
- EA2165:** A RANDOMIZED PHASE II PLACEBO CONTROLLED STUDY OF NIVOLUMAB AFTER COMBINED MODALITY THERAPY (CMT) IN HIGH RISK ANAL CANCER **DR. R. AUER**
- 10:00 CLOSING REMARKS